---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-000123"
form_type: "8-K"
ticker: "PASG"
cik: "0001787297"
company_name: "Passage BIO, Inc."
filed_at: "2023-01-09T23:59:59+00:00"
generated_at: "2026-06-20T18:04:44.277614+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "medium"
source: SEC EDGAR
---

# Passage Bio reports ~$190M cash as of Dec 31, 2022; runway into H1 2025

## Summary
- Preliminary unaudited cash, equivalents and marketable securities of ~$190M at Dec 31, 2022.
- Cash runway expected to fund operating expenses and capex into first half of 2025.
- Update provided in January 9, 2023 corporate presentation; figures subject to audit.
- No other financial results or guidance changes disclosed.

## SEC filing metadata
- accession: 0001558370-23-000123
- form_type: 8-K
- ticker: PASG
- cik: 0001787297
- company_name: Passage BIO, Inc.
- filed_at: 2023-01-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: medium
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787297/000155837023000123/0001558370-23-000123-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787297/000155837023000123/pasg-20230109x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-000123
- JSON: https://secwatch.observer/filing/0001558370-23-000123.json
- Plain text: https://secwatch.observer/filing/0001558370-23-000123.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.